Pantocalcin in Management and Rehabilitation of Patients with Neurodegenerative Disorders
Management of patients with neurodegenerative disorders is a challenging process. Due to late onset and complicated pathogenesis with involvement of multiple neurotransmitter systems, treatment of neurodegenerative disorders demands use of well tolerated medicines with good safety profiles. Pantocalcin is one of that kind of medicines. It is a derivative of hopantenic acid which affects the GABA receptor complex (GABA - g-aminobutyric acid). GABAergic processes are involved in the pathogenesis of Parkinson disease and other late-onset neurodegenerative disorders with movement and cognitive deficits. For that reason, Pantocalcin can be considered as a promising therapeutic option in that cohort of patients. Pantocalcin's targets and diverse effects are discussed in the paper. Authors' experience of Pantocalcin use in the elderly patients with neurodegenerative disorders (Parkinson disease, essential tremor, spinocerebellar ataxias, etc.) is presented. Among other products with nootropic effects, Pantocalcin has a better safety profile and can be used both in hospitals and within outpatient service.